Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE).
Over the last decades, the development of new drugs has allowed cancer patients to experience several lines of chemotherapy, the objective of which is a long term stabilization of the tumour. The objectives of this work was to delineate a composite index of relative antitumoural efficacy (In-RATE) of a regimen over another, including response rate (RR), median time to progression (TTP) and progression rate (PR). When considering two treatments a and b, the In-RATE was defined as RRa/RRb x TTPa/TTPb x PRb/PRa. Values significantly superior or inferior to 1 reveal an advantage for treatment a or b, respectively. The applicability of the In-RATE to published randomized trials in four frequent tumour types (colorectal, non-small cell lung, advanced ovarian and metastatic breast cancers) was suggested to more precisely distinguish the effects of different drugs, and sometimes to detect a significant difference when the published data did not conclude to statistical difference.
Hôpital Edouard-Herriot, Oncologie médicale, Pavillon E, 5 place d'Arsonval, 69437 Lyon Cedex 03, France. blay@lyon.fnclcc.fr
Jean-Yves
JY
Blay
Serge
S
Koscielny
Jean
J
Trédaniel
Bernard
B
Asselain
François
F
Goldwasser
Jean-Louis
JL
Misset
Cécile
C
de Labareyre
Charles
C
Hagège
Hervé
H
Bismut
Michel
M
Marty
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation / Q000379:methods*; D006801:Humans; D007700:Kinetics; D008962:Models, Theoretical; D012189:Retrospective Studies; D016896:Treatment Outcome
D000970:Antineoplastic Agents